Loading clinical trials...
Loading clinical trials...
Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children (6 to Less Than 12 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL- Cholesterol
Conditions
Interventions
Inclisiran
Placebo
Locations
66
United States
UC San Francisco Medical Center
San Francisco, California, United States
UC San Francisco Medical Center
San Francisco, California, United States
Children's National Hospital
Washington D.C., District of Columbia, United States
Childrens National Hospital
Washington D.C., District of Columbia, United States
Excel Medical Clinical Trials LLC
Boca Raton, Florida, United States
Icahn School of Med at Mt Sinai
New York, New York, United States
Start Date
December 9, 2024
Primary Completion Date
March 21, 2028
Completion Date
April 15, 2029
Last Updated
November 21, 2025
NCT04656028
NCT07102511
NCT05218005
NCT03501875
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions